A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Steven LE GOUILL, Pr
Nantes University Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu Angers
Angers, France
- Chu de Dijon
Dijon, France
- Hôpital Claude Huriez - Chru de Lille
Lille, France
- Hôpital Saint Eloi
Montpellier, France
- Chu de Nantes
Nantes, France
- Hôpital Du Haut Lévêque
Pessac, France
- Chu Rennes
Rennes, France
- Derriford Hospital _ Plymouth Hospitals Nhs Trust
Plymouth, Devon, United Kingdom
- University of Southampton
Southampton, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Oct 2015
- Primary completion
- 30 Apr 2019
- Completion
- 13 May 2025
- Last update posted
- 24 Jul 2025
- Registered enrollment
- 48
- Registry id
- NCT02558816
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.